2-bromopalmitate

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Animals1

Outcomes

Aβ deposition

downin mice1

1 study

2-bromopalmitate decreases Aβ deposition in mice.
“Chronic intranasal administration of 2-BP restored synaptic plasticity, reduced hippocampal Aβ deposition, improved cognitive function, and extended lifespan in both male and female 3×Tg-AD mice.”
Animalsin 3xTg-AD micechronic intranasal administrationhippocampusboth male and females
Aberrant Protein S‐Palmitoylation: A Novel Therapeutic Target in Alzheimer's Disease
AAIC 2025 abstract23 Dec 2025

Latest

1 in 12 months

AAIC 2025 Abstract24 Dec

Aberrant Protein S‐Palmitoylation: A Novel Therapeutic Target in Alzheimer's Disease

Experiments in miceMechanisms

Paper

2-bromopalmitate

Outcomes

Latest

Aberrant Protein S‐Palmitoylation: A Novel Therapeutic Target in Alzheimer's Disease

Related